drugset / Trial / NCT00004157

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

NCT00004157

Treatment

Summary

RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side effects after transplant. PURPOSE: Phase II trial to study the effectiveness of interleukin-11 plus filgrastim prior to peripheral stem cell transplantation in patients who have non-Hodgkin's lymphoma, Hodgkin's disease, breast cancer, or other solid tumors.

Timeline

Start
2000-08
Primary completion
2002-04
Completion
2002-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-11 Protein / enzyme biologic Subcutaneous
Subject filgrastim Protein / enzyme biologic Subcutaneous